ESAs In Renal Disease: Risk/Benefit Differs With Disease Stage, Amgen Says
Executive Summary
Medicare coverage policy for erythropoiesis-stimulating agents in patients with chronic kidney disease should recognize that the ESA needs of patients are very different for those who are on dialysis versus those who are not, Amgen said in recent comments to the Centers for Medicare and Medicaid Services
You may also be interested in...
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term
Delaying Inclusion Of Oral-Only ESRD Drugs In Bundled Payment Gives Short-Term Reprieve To Genzyme, Amgen
Although manufacturers and other stakeholders were unable to convince CMS to change its stance on including oral-only drugs to treat end-stage renal disease in a new prospective payment system, the agency's decision to delay that step for three years is being viewed as a somewhat positive result for Amgen and Genzyme in the short term
MedCAC Review Of ESAs In Renal Disease To Help Determine Need For NCD
The Medicare Evidence Development and Coverage Advisory Committee's review of the use of erythropoiesis-stimulating agents in chronic kidney disease is a first step toward determining whether the Centers for Medicare and Medicaid Services should open a national coverage determination process on Medicare payments for such treatment, according to CMS Chief Medical Officer Barry Straube